Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

被引：0
|
作者：
Zhang, Xiaoying [1 ]
机构：
[1] Shandong Univ, Qilu Hosp, Dept Geriatr, Jinan 250012, Peoples R China
来源：
GLOBAL MEDICAL GENETICS | 2021年 / 08卷 / 04期
关键词：
D O I：
10.1055/s-0041-1731067
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [21] Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
    Alfaro Autor, C.
    Romero, A.
    Calvo De Juan, V.
    Franco, F.
    Sanchez Romero, E.
    Ortiz Cortes, N.
    Sanz Moreno, S.
    Rodriguez Festa, A.
    Serna Blasco, R.
    Barquin Del Romo, M.
    Provencio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1036 - S1036
  • [22] Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib
    Kim, Taeyun
    Choe, Junsu
    Shin, Sun Hye
    Jeong, Byeong-Ho
    Lee, Kyungjong
    Kim, Hojoong
    Lee, Se-Hoon
    Um, Sang-Won
    PLOS ONE, 2024, 19 (09):
  • [23] Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review
    Yamaguchi, Fumihiro
    Kato, Eisuke
    Wakabayashi, Aya
    Shikama, Yusuke
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) : 127 - 131
  • [24] De novo EGFR T790M mutation in lung cancer patients harboring sensitive EGFR mutations
    Lee, Youngjoo
    Lee, Geon Kook
    Lee, Yeon-Su
    Zhang, Wenji
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
    Zhang, X.
    Wu, Y-L.
    Chen, Y.
    Zhang, H.
    Wu, G.
    Lu, Y.
    Liang, Z.
    Hu, Y.
    Cheng, Y.
    Wang, J.
    Ying, J.
    Liu, W.
    Liang, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
  • [26] Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
    Kudo, Kenichiro
    Ohashi, Kadoaki
    Makimoto, Go
    Higo, Hisao
    Kato, Yuka
    Kayatani, Hiroe
    Kurata, Yasuko
    Takami, Yoichiro
    Minami, Daisuke
    Ninomiya, Takashi
    Kubo, Toshio
    Ichihara, Eiki
    Sato, Akiko
    Hotta, Katsuyuki
    Yoshino, Tadashi
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    MOLECULAR ONCOLOGY, 2017, 11 (06): : 670 - 681
  • [27] Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
    Maekinen, Netta
    Zhou, Meng
    Bemus, Meredith
    Nevin, Julius
    Nag, Anwesha
    Chen, Ruthia
    Colson, Yolonda L.
    Thorner, Aaron R.
    Oxnard, Geoffrey R.
    Meyerson, Matthew
    Sholl, Lynette M.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):
  • [28] Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
    Macerola, Elisabetta
    Bruno, Rossella
    Prediletto, Irene
    Sensi, Elisa
    Chella, Antonio
    Landi, Lorenza
    Ali, Greta
    Fontanini, Gabriella
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1207 - S1207
  • [29] Acquired T790M resistance do afatinib in EGFR mutated lung adenocarcinoma
    Miyazaki, Kunihiko
    Sato, Shinya
    Kodama, Takahide
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2016, 64 (04): : 317 - 318
  • [30] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Sha Liu
    Tao Pan
    Ming-Kun Wang
    Jie Wang
    Shuang Zhang
    Ping Zhou
    Clinical Drug Investigation, 2022, 42 : 459 - 464
12345